Lead Product(s): ALT-B4
Therapeutic Area: Oncology Product Name: ALT-B4
Highest Development Status: Discovery Platform Product Type: Large molecule
Deal Size: $3,881.0 million Upfront Cash: $16.0 million
Deal Type: Licensing Agreement June 24, 2020
Under the terms of the agreement, Alteogen has granted worldwide rights for TTPC to develop multiple products in combination with ALT-B4.